A Biotech Bash - Recs and Wrecks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bash - Recs and Wrecks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (99)	8/31/1997 1:04:00 PM
From: Mark F. Beno	of 171

Antex Biologics (ANTX) - Biotech secret Anyone interested in the biotech steal of the century should look into Antex Biologics (ANTX) (formerly MicroCarb). The stock is trading at 0.68/share with 22 million shares outstanding, but the cash on hand is 6 million, and they have strategic alliances with Smith Kline (worth up to $30 million presently), the US Dept. of Defense, and Pasteur Merieux (a subsidiary of Rhone Polouc). Smith Kline most likely will announce an increased commitment and additional funding to the company before October 1997. There are two vaccines in phase I clinical trials (for H.pylori and otitis media) and one vaccine in phase II clinical trials for Campylobacter. Vaccines in preclinical development include Chlamydia and Shigella. The company owns patents on its key vaccine technologies, and additional major patent filings occurred in the first quarter of this year. The company also has an E. coli toxin test that is more sensitive than those already on the market. An announcement with a manufacturer/distributer may be imminent. For a detailed discussion of the Antex business plan, check out the companies SEC filings.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next